Literature DB >> 15660505

Andropause: is androgen replacement therapy indicated for the aging male?

Rabih A Hijazi1, Glenn R Cunningham.   

Abstract

The number of men in the United States > or =65 years of age is projected to increase from 14,452,000 in 2000 to 31,343,000 in 2030. Approximately 30% of men 60-70 years of age and 70% of men 70-80 years of age have low bioavailable or free testosterone levels. Symptoms and findings of testosterone deficiency are similar to those associated with aging. They include loss of energy, depressed mood, decreased libido, erectile dysfunction, decreased muscle mass and strength, increased fat mass, frailty, osteopenia, and osteoporosis. Several small clinical trials indicate that testosterone replacement therapy can improve many of these findings; however, the studies have not been powered to assess potential risks, such as the need for invasive treatment of benign prostatic hyperplasia, development of a clinical prostate cancer, or cardiovascular events. Thus, the benefit/risk ratio of testosterone replacement therapy in aging men is not known.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15660505     DOI: 10.1146/annurev.med.56.082103.104518

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  24 in total

Review 1.  Discovery and therapeutic promise of selective androgen receptor modulators.

Authors:  Jiyun Chen; Juhyun Kim; James T Dalton
Journal:  Mol Interv       Date:  2005-06

Review 2.  Can endocrine disruptors influence neuroplasticity in the aging brain?

Authors:  Bernard Weiss
Journal:  Neurotoxicology       Date:  2007-02-04       Impact factor: 4.294

3.  Gene-chemical interactions in the developing mammalian nervous system: Effects on proliferation, neurogenesis and differentiation.

Authors:  Donald A Fox; Lisa Opanashuk; Aleksander Zharkovsky; Bernie Weiss
Journal:  Neurotoxicology       Date:  2010-04-08       Impact factor: 4.294

4.  Delayed testicular aging in pituitary adenylate cyclase-activating peptide (PACAP) null mice.

Authors:  Arnaud Lacombe; Vincent Lelievre; Charles E Roselli; Wael Salameh; Yan-he Lue; Gregory Lawson; Jean-Marc Muller; James A Waschek; Eric Vilain
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

Review 5.  The effects of opioids and opioid analogs on animal and human endocrine systems.

Authors:  Cassidy Vuong; Stan H M Van Uum; Laura E O'Dell; Kabirullah Lutfy; Theodore C Friedman
Journal:  Endocr Rev       Date:  2009-11-10       Impact factor: 19.871

6.  Effect of exercise on serum sex hormones in men: a 12-month randomized clinical trial.

Authors:  Vivian N Hawkins; Karen Foster-Schubert; Jessica Chubak; Bess Sorensen; Cornelia M Ulrich; Frank Z Stancyzk; Stephen Plymate; Janet Stanford; Emily White; John D Potter; Anne McTiernan
Journal:  Med Sci Sports Exerc       Date:  2008-02       Impact factor: 5.411

Review 7.  A practical guide to male hypogonadism in the primary care setting.

Authors:  P Dandona; M T Rosenberg
Journal:  Int J Clin Pract       Date:  2010-05       Impact factor: 2.503

8.  Cognition is not modified by large but temporary changes in sex hormones in men.

Authors:  Laura A Young; Michelle B Neiss; Mary H Samuels; Charles E Roselli; Jeri S Janowsky
Journal:  J Clin Endocrinol Metab       Date:  2009-10-30       Impact factor: 5.958

9.  The associations between serum sex hormones, erectile function, and sex drive: the Olmsted County Study of Urinary Symptoms and Health Status among Men.

Authors:  Naomi M Gades; Debra J Jacobson; Michaela E McGree; Jennifer L St Sauver; Michael M Lieber; Ajay Nehra; Cynthia J Girman; George G Klee; Steven J Jacobsen
Journal:  J Sex Med       Date:  2008-07-04       Impact factor: 3.802

10.  Selective androgen receptor modulator RAD140 is neuroprotective in cultured neurons and kainate-lesioned male rats.

Authors:  Anusha Jayaraman; Amy Christensen; V Alexandra Moser; Rebekah S Vest; Chris P Miller; Gary Hattersley; Christian J Pike
Journal:  Endocrinology       Date:  2014-01-15       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.